Physician profile
Muhammad H Bashir
NPI 1881027662
$6,861.76
in general payments reported to CMS, 2019-2025
14 companies · $107 in 2025
The $107 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $461 · 2020: $24.13 · 2021: $848 · 2022: $3,687 · 2023: $1,373 · 2024: $361 · 2025: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $960 · Travel and Lodging: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $959.65 |
| Travel and Lodging | $882.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus Corporation of The Americas | $3,111.99 | 2022 | |
| Boston Scientific Corporation | $2,313.52 | 2019-2025 | Spyglass, Exalt Model D, Spyglass Discover |
| Abbvie INC. | $499.78 | 2022-2024 | Rinvoq |
| Gilead Sciences, INC. | $149.13 | 2019-2020 | |
| Evoke Pharma, INC. | $133.31 | 2023 | Gimoti |
| Mallinckrodt Hospital Products INC. | $124.16 | 2024 | Terlivaz |
| Nestle Healthcare Nutrition INC. | $120.00 | 2021 | |
| Omega Medical Imaging, LLC | $118.62 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $101.20 | 2023 | Zeposia |
| Cook Medical LLC | $69.01 | 2021-2022 | |
| Olympus America INC. | $44.45 | 2024 | Hanarostent Esophagus Tts(Ccc) |
| Takeda Pharmaceuticals U.S.A., INC. | $40.28 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.50 | 2023 | Xifaxan |
| Ardelyx, INC. | $17.81 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Bashir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.